The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread
Clinical trial NCT03659136 · COMPLETED
Trial details
- NCT number
- NCT03659136
- Sponsor
- Boehringer Ingelheim
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-11-28
- Primary completion
- 2021-08-30
- Enrollment
- 103
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.